Compare BTCS & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTCS | MCRB |
|---|---|---|
| Founded | 2008 | 2010 |
| Country | United States | United States |
| Employees | N/A | 103 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.0M | 140.7M |
| IPO Year | N/A | 2015 |
| Metric | BTCS | MCRB |
|---|---|---|
| Price | $2.86 | $15.86 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | $7.00 | ★ $14.33 |
| AVG Volume (30 Days) | ★ 1.2M | 70.7K |
| Earning Date | 11-14-2025 | 11-05-2025 |
| Dividend Yield | ★ 1.65% | N/A |
| EPS Growth | ★ 644.42 | N/A |
| EPS | ★ 1.76 | 0.62 |
| Revenue | ★ $11,724,983.00 | $351,000.00 |
| Revenue This Year | $248.05 | N/A |
| Revenue Next Year | $41.01 | N/A |
| P/E Ratio | ★ $1.72 | $25.12 |
| Revenue Growth | ★ 464.28 | N/A |
| 52 Week Low | $1.25 | $6.53 |
| 52 Week High | $8.49 | $29.98 |
| Indicator | BTCS | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 44.54 | 49.65 |
| Support Level | $2.82 | $14.50 |
| Resistance Level | $3.07 | $15.41 |
| Average True Range (ATR) | 0.19 | 0.82 |
| MACD | 0.01 | 0.13 |
| Stochastic Oscillator | 41.84 | 80.17 |
BTCS Inc. ("BTCS" or the "Company"), short for Blockchain Technology Consensus Solutions, is a U.S.-based Ethereum-first blockchain technology company committed to driving scalable revenue and ETH accumulation through its hallmark strategy, the DeFi/TradFi Accretion Flywheel, an integrated approach to capital formation and blockchain infrastructure. By combining decentralized finance ("DeFi") and traditional finance ("TradFi") mechanisms with its blockchain infrastructure operations, comprising NodeOps (staking) and Builder+ (block building), BTCS offers one of the most sophisticated opportunities for leveraged ETH exposure, driven by scalable revenue generation and a yield-focused ETH accumulation strategy. Discover how BTCS offers operational and financial leveraged exposure to Ethereum through the public markets at www.btcs.com.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.